[ 메디채널 김갑성 기자 ] - The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in body weight compared to tirzepatide monotherapy.
- ASC47 low dose in combination with tirzepatide demonstrated statistically significantly greater increase in efficacy than ASC47 low dose in combination with semaglutide, 87% vs 55%, respectively, in the DIO mouse model.
- The combination of ASC47 low dose with tirzepatide also restored the body composition of obese mice to the level of healthy non-obese mice. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with the combination of ASC47 low dose with tirzepatide was similar to healthy non-obese mice, 60.4% vs 62.0% respectively.
HONG KONG, Aug. 13, 2025 -- Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces encouraging efficacy results from its study in diet-induced obese (DIO) mice combining ASC47, a first-in-class muscle-preserving weight loss drug candidate for the treatment of obesity, with tirzepatide.
ASC47 is an adipose-targeted, once-monthly subcutaneously (SQ) injected thyroid hormone receptor beta (THRβ) selective small molecule agonist, discovered and developed in-house at Ascletis. ASC47 possesses unique and differentiated properties to enable adipose targeting, resulting in dose-dependent high drug concentrations in the adipose tissue.
The objective of the DIO mouse study was to compare a low dose of ASC47 (9 mg/kg, single dose) combined with tirzepatide (3 nmol/kg, SQ, once daily) against tirzepatide monotherapy (3 nmol/kg, SQ, once daily). The treatment duration in the DIO mice was 14 days. Results showed that the combination of ASC47 low dose with tirzepatide was superior to tirzepatide monotherapy, with an average total body weight reduction of 38.1% compared to 20.4%, achieving 87% more relative weight loss compared to tirzepatide monotherapy (Table 1). In comparison, the combination of ASC47 low dose with semaglutide demonstrated statistically significantly lower efficacy (p=0.006) in the DIO mouse study, showing a 55% greater reduction in body weight compared to semaglutide monotherapy.
Table 1. ASC47 low dose demonstrated greater efficacy with tirzepatide than semaglutide
Group
| Dosing
| Total body
weight change
| Greater body weight
|
Obese mice treated
| Tirzepatide,
3 nmol/kg,
SQ, QD
| -20.4 %
| -
|
Obese mice treated
| ASC47,
9 mg/kg,
SQ, a single dose
+
tirzepatide,
3 nmol/kg,
SQ, QD
| -38.1%
(p<0.0001 vs
| 87 %
|
Obese mice treated
| Semaglutide,
30 nmol/kg,
SQ, QD
| -23.1 %
| -
|
Obese mice treated
| ASC47,
9 mg/kg,
SQ, a single dose
+
semaglutide,
30 nmol/kg,
SQ, QD
| -35.9%
(p<0.0001 vs
| 55 %
|
Note: Treatment duration: 14 days for tirzepatide monotherapy and ASC47/tirzepatide combination therapy; 28 days for semaglutide monotherapy and ASC47/semaglutide combination therapy; Obese mice: diet-induced obese mice; SQ: subcutaneous; QD: once daily.
The combination of ASC47 low dose with tirzepatide also restored the body composition of obese mice to the level of healthy non-obese mice. At the end of treatment, the percentage of total muscle mass over the total body weight of obese mice treated with ASC47 low dose and tirzepatide (60.4%) was similar to healthy non-obese mice (62.0%), indicating healthy weight loss. Tirzepatide monotherapy was unable to restore body composition to healthy levels.
"These preclinical data build upon a body of evidence demonstrating the potential of ASC47 as an important therapeutic approach for the treatment of obesity." said Jinzi Jason Wu, Ph.D., Founder, Chairman and CEO of Ascletis, "With topline data in participants with obesity from the combination study of ASC47 with semaglutide coming soon, we look forward to the combinations of ASC47 with other incretin drugs including tirzepatide in future clinical trials."
About Ascletis Pharma Inc.
Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases. Utilizing its proprietary Artificial Intelligence-Assisted Structure-Based Drug Discovery (AISBDD) Platform and Ultra-Long-Acting Platform (ULAP), Ascletis has developed multiple drug candidates in-house, including its lead program, ASC30, a small molecule GLP-1R agonist in development as a once-daily oral tablet and once-monthly subcutaneous injection for weight management. Ascletis is listed on the Hong Kong Stock Exchange (1672.HK).
For more information, please visit www.ascletis.com.
Contact：
Peter Vozzo
ICR Healthcare
443-231-0505 (U.S.)
Peter.vozzo@icrhealthcare.com
Ascletis Pharma Inc. PR and IR teams
+86-181-0650-9129 (China)
pr@ascletis.com
ir@ascletis.com
